R&D | February 24, 2026
Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Subscribe To Our Newsletter & Stay Updated
